Timing of treatment initiation in Parkinson's disease: a need for reappraisal?
about
Interventions for improving medication adherence in patients with idiopathic Parkinson's diseaseA review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's diseaseDopamine agonists in Parkinson's diseaseParallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.Post hoc Parkinson's disease: identifying an uncommon disease in the Cardiovascular Health StudyPramipexole for the treatment of early Parkinson's disease.How to optimize the treatment of early stage Parkinson's disease.Caffeine for treatment of Parkinson disease: a randomized controlled trial.A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.100 years and counting: prospects for defeating Alzheimer's diseaseAutosomal dominant Parkinson's disease and the route to new therapies.Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.Progress in neuroprotection in Parkinson's disease.Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?How should we treat a patient with early Parkinson's disease?Safinamide in the treatment of Parkinson's disease.Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?Milestones in movement disorders clinical trials: advances and landmark studies.Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.The significance of defining preclinical or prodromal Parkinson's disease.Trial designs used to study neuroprotective therapy in Parkinson's disease.Treatment in early Parkinson's disease: the Norwegian ParkWest study.The role of neuroplasticity in dopaminergic therapy for Parkinson disease.Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.Early versus delayed initiation of pharmacotherapy in Parkinson's disease.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Early synaptic dysfunction in Parkinson's disease: Insights from animal models.The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trialOptimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.Parkinson's disease misdiagnosed as stroke.Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.Long-term efficacy of rasagiline in early Parkinson's disease.Self-reported health in people with Parkinson's disease left untreated at diagnosis.
P2860
Q24194607-901ED92B-3CC4-476F-9860-FBF7555F6044Q27311651-D18FCAE4-A7FE-4AD5-9B62-3C5949DA407EQ28276692-4D0D3571-1D33-4AD4-9332-85FF8B4DFA4EQ30538394-2D93AD89-F2FE-4DCD-AF29-CB92FCF2D00CQ33768106-8A5C9791-35AE-473F-A420-79CAFC47BBF9Q33785397-7DB9C2BE-9A84-4FE9-9869-9B5926FDCE8FQ34027880-F6526478-B31A-475D-8616-8A20C8525EDAQ34297681-4CBB0261-9102-435C-B059-6BB83375A340Q34630735-422D4551-2977-4315-B60F-6C424246B77AQ35599297-ECAE0CE7-A404-42AA-A991-2AFC322F307CQ36149963-823E3DD0-86F2-4187-9A01-5DCA5A432A2AQ36227451-D042D476-8BAA-4934-8FC8-46C6D20EC360Q36643419-B90E6991-7160-44E7-84D4-3BDD7206CA72Q36847250-F93CCC90-5519-46D0-94DB-D6B9177B03C8Q37022421-44D31170-5DE9-47B3-B31F-AB0C7FDEE6E9Q37114112-A8FA36D5-8C5D-4A63-8D35-88C353C9652AQ37382891-452D05E2-AD1B-499C-8991-708E9CDF107BQ37724555-3019691F-7469-49A7-9019-B39F3F95B7BFQ37775098-C84BAEFA-EC45-42BF-A6E3-857367A7F53DQ37779808-A05F42BA-4341-40FF-B62B-FE15443E272CQ37846235-92951DD4-B52C-41BA-8A6E-34C9809A8840Q37865446-43A5C0BA-D231-461C-A5E2-AE6E6BC32D73Q37882584-EFF65CF1-1827-43FF-B61E-BC53C7F4B861Q37905769-14B9D49E-5F01-4E3C-A0BE-9EB170BDFC45Q37963572-168FE238-AA9C-439D-A3A5-1C384A44AE1CQ37979869-3D8CA1B3-1965-495D-A257-F9E4950B6DF4Q38003068-EB2C5D60-9941-42E4-934C-489F24DA78E3Q38038539-8B0723BB-2606-47EF-8043-14B815E2D9E6Q38063341-7A3D4281-ED2C-4106-918A-5E777E45425AQ38099197-5C622905-419D-4526-8944-C21C9B8CFD5AQ38134903-C0F8DF31-5A41-40CE-ABF1-4DB3D2DE0238Q38206403-9A980309-DEE8-47D1-A5ED-D8EF2D86AE4BQ38545359-F27E2C69-DC79-467C-B9C7-875DD2D78329Q38837604-C23B6A90-4DE1-4385-97BD-A8A3E6159496Q39714311-FAABE9B8-C9E2-4082-81AB-309096A20E95Q42392773-C35B24A2-B466-4587-91EB-09C785163CBBQ42584633-58B5276C-5FBA-45F2-B42C-0E8442DD8891Q42626399-F601C966-591C-4F43-813A-1951F92B8B40Q42661912-BCE9F8E8-50B1-4D62-84D9-749ACEDBD4C7Q42766070-CAC2A238-ED75-4CD7-AF91-A1D943AB59F2
P2860
Timing of treatment initiation in Parkinson's disease: a need for reappraisal?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Timing of treatment initiation in Parkinson's disease: a need for reappraisal?
@ast
Timing of treatment initiation in Parkinson's disease: a need for reappraisal?
@en
type
label
Timing of treatment initiation in Parkinson's disease: a need for reappraisal?
@ast
Timing of treatment initiation in Parkinson's disease: a need for reappraisal?
@en
prefLabel
Timing of treatment initiation in Parkinson's disease: a need for reappraisal?
@ast
Timing of treatment initiation in Parkinson's disease: a need for reappraisal?
@en
P356
P1433
P1476
Timing of treatment initiation in Parkinson's disease: a need for reappraisal?
@en
P2093
Jose Obeso
P2860
P304
P356
10.1002/ANA.20789
P577
2006-03-01T00:00:00Z